Literature DB >> 30516858

Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.

Sang Soo Lee1,2,3, Cha Young Kim4, Bo Ra Kim1, Ra Ri Cha1,3, Wan Soo Kim1,3, Jin Joo Kim1,3, Jae Min Lee1,2,3, Hong Jun Kim1,2, Chang Yoon Ha1,2, Hyun Jin Kim1,2,3, Tae Hyo Kim1,2, Woon Tae Jung1,2, Ok-Jae Lee1,2.   

Abstract

Although hepatitis C virus (HCV) genotype 3 infection is thought to be an important risk factor for hepatocellular carcinoma (HCC), current evidence is limited because only a few Western studies have evaluated the occurrence of HCC in patients with HCV genotype 3 infection. We evaluated the impact of genotype 3 and non-3 on HCC incidence and on disease progression in chronic HCV patients; this is the first study reporting such findings in an Asian population. We performed a retrospective cohort study using the data of 1448 consecutive chronic HCV patients evaluated at three centres in Korea between January 2005 and December 2016. Of these, 604, 675 and 169 had genotype 1, genotype 2 and genotype 3 HCV infections, respectively. Over a mean follow-up period of 53.2 months, 75 and 143 patients of all the patients developed HCC and experienced disease progression, respectively. The incidences of HCC were 1.10, 0.92 and 2.50 per 100 person-years, and those of disease progression were 1.95, 1.62 and 6.72 per 100 person-years for HCV genotypes 1, 2 and 3, respectively. In multivariate Cox regression analysis, genotype 3 was associated with an increased risk of HCC (hazard ratio [HR] = 4.26, 95% confidence interval [CI] = 2.02-8.97) and an increased risk of disease progression (HR = 4.88, 95%; CI = 2.94-8.08). Our study proposes that HCV genotype 3 is an independent risk factor for HCC and disease progression in chronic HCV patients.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Korea; disease progression; genotype 3; hepatitis C virus; hepatocellular carcinoma

Mesh:

Year:  2019        PMID: 30516858     DOI: 10.1111/jvh.13047

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  5 in total

Review 1.  Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment.

Authors:  Leonardo Stella; Francesco Santopaolo; Antonio Gasbarrini; Maurizio Pompili; Francesca Romana Ponziani
Journal:  World J Gastroenterol       Date:  2022-06-07       Impact factor: 5.374

2.  Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma.

Authors:  Hye Kyong Park; Sang Soo Lee; Chang Bin Im; Changjo Im; Ra Ri Cha; Wan Soo Kim; Hyun Chin Cho; Jae Min Lee; Hyun Jin Kim; Tae Hyo Kim; Woon Tae Jung; Ok-Jae Lee
Journal:  BMC Cancer       Date:  2019-08-20       Impact factor: 4.430

Review 3.  Genotype 3-hepatitis C virus' last line of defense.

Authors:  Dorota Zarębska-Michaluk
Journal:  World J Gastroenterol       Date:  2021-03-21       Impact factor: 5.742

4.  Infection with the hepatitis C virus causes viral genotype-specific differences in cholesterol metabolism and hepatic steatosis.

Authors:  David A Sheridan; Isaac Thom Shawa; E Louise Thomas; Daniel J Felmlee; Simon H Bridge; Dermot Neely; Jeremy F Cobbold; Elaine Holmes; Margaret F Bassendine; Simon D Taylor-Robinson
Journal:  Sci Rep       Date:  2022-04-01       Impact factor: 4.379

Review 5.  Direct-acting Antiviral Regimens for Patients with Chronic Infection of Hepatitis C Virus Genotype 3 in China.

Authors:  Xiaozhong Wang; Lai Wei
Journal:  J Clin Transl Hepatol       Date:  2021-05-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.